Hyderabad-headquartered Rockwell Industries, a pioneering commercial cold chain appliances manufacturer, on Thursday launched CHILLERMIL, the world’s first chiller/freezer powered by hybrid (solar and wind) renewable energy, that would be ideal for storing vaccines, lifesaving medicines, including those for Covid-19 vaccines at the desired temperature. The company also rolled out their new Covid-19 vaccine freezer series.
The Intelligently designed Rockwell’s CHILLERMILL, and WHO PQS (World Health Organisation PQS) certified the new Covid-19 Freezer Series, will be manufactured at its state-of-the-art manufacturing facility in Medchal, Hyderabad. The entire system is certified by the National Institute of Pharmaceutical Education & Research (NIPER) Hyderabad.
Jayesh Ranjan, Principal Secretary, Government of Telangana for the Industries & Commerce (I&C) and Information Technology (IT), formally launched the new range of Covid-19 vaccines chillers, a simple plug and play standalone unit, powered by Solar Mills, a hybrid (wind and solar) energy solution, manufactured by Wind Stream Energy Technologies ideal for remote areas where availability of electricity is not stable. The Hybrid Renewable System, comprising Savonius vertical axis wind turbines, along with a Solar Module enables, the refrigerator to run 24/7 on power stored in batteries. Solar Mills are also being used in powering critical applications of Defence forces, Railways and Telecom domain.
Commending Rockwell for its need of the hour technological innovation, and its new Covid-19 vaccine focussed Hybrid Renewable Energy driven CHILLERMILL and the WHO certified new Covid-19 Freezer series, Jayesh Ranjan said: “Governments and immunisation programmes rely on a complicated cold chain of freezers and temperature-controlled conditions and Rockwell has developed the much-needed refrigeration technology to address these challenges to preserve vaccine, healthcare products, and other deep-freezing applications.”
The company is in active discussion with leading vaccine players nationally and internationally to supply CHILLERMILL. “We expect to close in orders worth Rs 25 crore this year and hope to achieve Rs 50 crore by the end of 2022,” Ashok Gupta added.
